Serum-derived exosomal miR-7977 combined with miR-451a as a potential biomarker for pancreatic ductal adenocarcinoma.

IF 3.4 2区医学 Q2 ONCOLOGY BMC Cancer Pub Date : 2025-02-19 DOI:10.1186/s12885-025-13659-2

Jia Chen, Xue Zhang, Guanyi Zhang, Fan Zhu, Weiwei Liu

{"title":"Serum-derived exosomal miR-7977 combined with miR-451a as a potential biomarker for pancreatic ductal adenocarcinoma.","authors":"Jia Chen, Xue Zhang, Guanyi Zhang, Fan Zhu, Weiwei Liu","doi":"10.1186/s12885-025-13659-2","DOIUrl":null,"url":null,"abstract":"Objectives: To explore the potential of serum exosomal miRNAs as novel biomarkers for pancreatic ductal adenocarcinoma (PDAC).Methods: Serum exosomal miRNAs were screened and verified by microarray analysis and quantitative real-time PCR (qRT-PCR) in patients with PDAC and healthy controls. The correlation between the clinical characteristics of PDAC and candidate exosomal miRNAs was analyzed, and the diagnostic performance of the candidate biomarkers was evaluated.Results: Serum exosomal miR-7977 and miR-451a were significantly upregulated in PDAC patients compared with healthy controls, and the levels of miR-7977 and miR-451a in serum exosomes were closely associated with the clinical stage and metastasis of PDAC patients. The area under curve (AUC) values of serum exosomal miR-7977 and miR-451a for PDAC were 0.825 and 0.804 in the training set and 0.796 and 0.830 in the validation set, respectively. A biomarker panel consisting of these two miRNAs resulted in a diagnostic power with an AUC of 0.901 in the training set and 0.918 in the validation set.Conclusions: Serum exosomal miR-7977 and miR-451a might be diagnostic biomarkers for PDAC. These two miRNAs, when combined, exhibit optimal diagnostic performance.","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"295"},"PeriodicalIF":3.4000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837301/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12885-025-13659-2","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To explore the potential of serum exosomal miRNAs as novel biomarkers for pancreatic ductal adenocarcinoma (PDAC).

Methods: Serum exosomal miRNAs were screened and verified by microarray analysis and quantitative real-time PCR (qRT-PCR) in patients with PDAC and healthy controls. The correlation between the clinical characteristics of PDAC and candidate exosomal miRNAs was analyzed, and the diagnostic performance of the candidate biomarkers was evaluated.

Results: Serum exosomal miR-7977 and miR-451a were significantly upregulated in PDAC patients compared with healthy controls, and the levels of miR-7977 and miR-451a in serum exosomes were closely associated with the clinical stage and metastasis of PDAC patients. The area under curve (AUC) values of serum exosomal miR-7977 and miR-451a for PDAC were 0.825 and 0.804 in the training set and 0.796 and 0.830 in the validation set, respectively. A biomarker panel consisting of these two miRNAs resulted in a diagnostic power with an AUC of 0.901 in the training set and 0.918 in the validation set.

Conclusions: Serum exosomal miR-7977 and miR-451a might be diagnostic biomarkers for PDAC. These two miRNAs, when combined, exhibit optimal diagnostic performance.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

血清来源的外泌体miR-7977联合miR-451a作为胰腺导管腺癌的潜在生物标志物。

目的：探讨血清外泌体mirna作为胰腺导管腺癌（PDAC）新生物标志物的潜力。方法：筛选PDAC患者和健康对照者血清外泌体mirna，并采用微阵列分析和实时荧光定量PCR （qRT-PCR）技术进行验证。分析PDAC临床特征与候选外泌体mirna之间的相关性，并评估候选生物标志物的诊断性能。结果：PDAC患者血清外泌体miR-7977和miR-451a与健康对照组相比显著上调，血清外泌体miR-7977和miR-451a水平与PDAC患者的临床分期和转移密切相关。血清外泌体miR-7977和miR-451a对PDAC的曲线下面积（AUC）值在训练集中分别为0.825和0.804，在验证集中分别为0.796和0.830。由这两种mirna组成的生物标志物小组的诊断能力在训练集中为0.901，在验证集中为0.918。结论：血清外泌体miR-7977和miR-451a可能是PDAC的诊断性生物标志物。当这两种mirna结合在一起时，表现出最佳的诊断性能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.